BIEL’s Emerging Role in Electrome’s Bioelectric Medicine Platform
1. Predicate Device Status
“Programmable applicator device platform based on 27.12 MHz carrier frequency, with FDA‑cleared predicate devices (ActiPatch/RecoveryRx/Sofpulse/OrthoCo).
Why this matters for BIEL
Establishes ActiPatch and RecoveryRx as the regulatory foundation for Electrome’s entire therapeutic platform.
Confirms BIEL’s devices as clinically validated, FDA‑cleared, and scalable hardware suitable for next‑generation bioelectric medicine.
Repositions BIEL from a small PEMF manufacturer to a core enabling technology provider for AI‑driven neuromodulation.
2. Exclusive OEM Contract
“Exclusive OEM contract with BioElectronics Corp (BIEL) for ActiPatch and RecoveryRx.”
Impact on BIEL
Secures exclusive supply revenue as Electrome scales across multiple indications.
Creates a locked‑in commercial relationship with a fast‑growing, AI‑powered therapeutics company.
Enhances BIEL’s leverage for future OEM partnerships by demonstrating real‑world adoption.
Strengthens the valuation narrative: BIEL’s hardware is the backbone of a programmable bioelectric medicine platform.
3. Regulatory Acceleration Through BIEL
“OEM agreement provides pre‑cleared regulatory and manufacturing channel for early sales.”
Impact on BIEL
Electrome’s first 510(k) submission is accelerated by BIEL’s existing FDA‑cleared devices.
BIEL becomes the regulatory shortcut for Electrome’s commercial entry.
Increases BIEL’s strategic indispensability—difficult to replace, easy to scale.
Creates a recurring pipeline of device orders tied to Electrome’s product launches.
4. Revenue Forecast Linked to OEM Channel
“2025: $0.6M (Q4 pilot launch through OEM / VA channel)”
Impact on BIEL
Early revenue is directly attributable to BIEL’s device supply.
VA channel access expands BIEL’s presence in high‑credibility government healthcare markets.
Demonstrates that the OEM partnership is already monetizing, not theoretical.
Summary of BIEL‑Relevant Impacts
Strategic Positioning
BIEL becomes the hardware backbone of Electrome’s AI‑driven bioelectric platform.
ActiPatch/RecoveryRx evolve from OTC devices into predicate technologies for programmable therapeutics.
BIEL gains strategic leverage within the broader neuromodulation ecosystem.
Revenue & Growth
OEM exclusivity ensures recurring device sales as Electrome scales.
Revenue begins in Q4 2025, with multi‑year expansion projected through 2028.
Potential for multi‑indication, high‑volume growth across clinical and consumer markets.
Regulatory & Clinical Credibility
Electrome’s regulatory pathway depends on BIEL’s cleared devices, creating a durable moat.
Association with Harvard, Tulane, VA, and Baylor trials elevates BIEL’s scientific legitimacy.
BIEL becomes a trusted, compliant hardware platform for emerging bioelectric therapies.
Market Expansion
Electrome’s distribution channels—VA, sports medicine, outpatient surgery, OTC retail—become indirect distribution for BIEL.
BIEL gains exposure to infection, oncology, concussion, and CNS indications through Electrome’s pipeline.
Investor Narrative
BIEL transitions from a PEMF device company to a platform enabler in a $140B therapeutic market.
OEM exclusivity and predicate status are high‑value catalysts for share price appreciation.
Creates a compelling story for PR, investor decks, and market awareness campaigns.
The Bigger Picture for BIEL
Electrome’s executive summary reframes BIEL as:
A critical supplier to a high‑growth, AI‑powered therapeutics company
The regulatory and hardware foundation for programmable bioelectric medicine
A beneficiary of Electrome’s clinical trials, partnerships, and distribution channels
A company with near‑term revenue and long‑term exponential upside
This is the strongest external validation BIEL has received in years—and it positions the company for a fundamentally different growth trajectory.
1. Predicate Device Status
“Programmable applicator device platform based on 27.12 MHz carrier frequency, with FDA‑cleared predicate devices (ActiPatch/RecoveryRx/Sofpulse/OrthoCo).
Why this matters for BIEL
Establishes ActiPatch and RecoveryRx as the regulatory foundation for Electrome’s entire therapeutic platform.
Confirms BIEL’s devices as clinically validated, FDA‑cleared, and scalable hardware suitable for next‑generation bioelectric medicine.
Repositions BIEL from a small PEMF manufacturer to a core enabling technology provider for AI‑driven neuromodulation.
2. Exclusive OEM Contract
“Exclusive OEM contract with BioElectronics Corp (BIEL) for ActiPatch and RecoveryRx.”
Impact on BIEL
Secures exclusive supply revenue as Electrome scales across multiple indications.
Creates a locked‑in commercial relationship with a fast‑growing, AI‑powered therapeutics company.
Enhances BIEL’s leverage for future OEM partnerships by demonstrating real‑world adoption.
Strengthens the valuation narrative: BIEL’s hardware is the backbone of a programmable bioelectric medicine platform.
3. Regulatory Acceleration Through BIEL
“OEM agreement provides pre‑cleared regulatory and manufacturing channel for early sales.”
Impact on BIEL
Electrome’s first 510(k) submission is accelerated by BIEL’s existing FDA‑cleared devices.
BIEL becomes the regulatory shortcut for Electrome’s commercial entry.
Increases BIEL’s strategic indispensability—difficult to replace, easy to scale.
Creates a recurring pipeline of device orders tied to Electrome’s product launches.
4. Revenue Forecast Linked to OEM Channel
“2025: $0.6M (Q4 pilot launch through OEM / VA channel)”
Impact on BIEL
Early revenue is directly attributable to BIEL’s device supply.
VA channel access expands BIEL’s presence in high‑credibility government healthcare markets.
Demonstrates that the OEM partnership is already monetizing, not theoretical.
Summary of BIEL‑Relevant Impacts
Strategic Positioning
BIEL becomes the hardware backbone of Electrome’s AI‑driven bioelectric platform.
ActiPatch/RecoveryRx evolve from OTC devices into predicate technologies for programmable therapeutics.
BIEL gains strategic leverage within the broader neuromodulation ecosystem.
Revenue & Growth
OEM exclusivity ensures recurring device sales as Electrome scales.
Revenue begins in Q4 2025, with multi‑year expansion projected through 2028.
Potential for multi‑indication, high‑volume growth across clinical and consumer markets.
Regulatory & Clinical Credibility
Electrome’s regulatory pathway depends on BIEL’s cleared devices, creating a durable moat.
Association with Harvard, Tulane, VA, and Baylor trials elevates BIEL’s scientific legitimacy.
BIEL becomes a trusted, compliant hardware platform for emerging bioelectric therapies.
Market Expansion
Electrome’s distribution channels—VA, sports medicine, outpatient surgery, OTC retail—become indirect distribution for BIEL.
BIEL gains exposure to infection, oncology, concussion, and CNS indications through Electrome’s pipeline.
Investor Narrative
BIEL transitions from a PEMF device company to a platform enabler in a $140B therapeutic market.
OEM exclusivity and predicate status are high‑value catalysts for share price appreciation.
Creates a compelling story for PR, investor decks, and market awareness campaigns.
The Bigger Picture for BIEL
Electrome’s executive summary reframes BIEL as:
A critical supplier to a high‑growth, AI‑powered therapeutics company
The regulatory and hardware foundation for programmable bioelectric medicine
A beneficiary of Electrome’s clinical trials, partnerships, and distribution channels
A company with near‑term revenue and long‑term exponential upside
This is the strongest external validation BIEL has received in years—and it positions the company for a fundamentally different growth trajectory.
2
